Pharmacy Times

JANUARY 3, 2024

Pharmacists involvement in HIV care and treatment has been shown to lead to clinically and statistically significant improvements in ART adherence, as well as greater viral load suppression for patients with HIV.

123

123

European Pharmaceutical Review

MARCH 11, 2024

Since the HIV epidemic began in the early 1980s, more than 85 million people have been diagnosed worldwide and about 40 million have died as a result of complications from the virus. 1 Now, four decades later, 39 million people around the world are living with HIV, primarily due to advances in treatment.

Immunization 95

Immunization 95

Fierce Pharma

FEBRUARY 20, 2024

This week on “The Top Line,” we’re speaking with Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled indiv | This week, we’re speaking with Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment (..)

86

86

Pharmacy Times

DECEMBER 18, 2023

Using information from clinical studies and her experiences working in the field, Stephanie Kirk describes treatment options that are on the horizon, and how removing stigma is key in HIV care.

144

144

Pharmafile

MARCH 7, 2024

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 clinical study assessing the combination of islatravir and lenacapavir for viral suppression in HIV treatment.

59

59

Hospital Pharmacy Europe

DECEMBER 7, 2023

HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV acquisition but greater provision is needed to meet the ‘large unmet need’ and maximise the potential of a national programme, say researchers who led a large trial of its use in England. HIV testing and PrEP is available for free from sexual health services.’

Hospitals 59

Hospitals 59

Pharmacy Times

DECEMBER 6, 2022

Dena Dillon, HIV clinical pharmacy specialist at the University of Iowa Health Care, discusses 2-drug regimens for individuals living with HIV.

123

123

Pharmacy Times

JUNE 22, 2023

Six-month preexposure prophylaxis (PrEP) dispensing supported by HIV self-testing resulted in PrEP adherence after 12 months and less visits to clinical sites.

122

122

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccines 145

Vaccines Immunization 145

Pharmacy Is Right For Me

AUGUST 10, 2022

I joined the Janssen Pharmaceutical Companies of Johnson & Johnson in 2007 as a Medical Science Liaison from the Rainbow Center for Women, Children, and Families in Jacksonville, Florida, where I served as an HIV Clinical Specialist and Clinical Assistant Professor at the University of Florida School of Pharmacy.

Vaccines 130

Vaccines Pharmaceutical Companies Pharmaceutical Companies 130

European Pharmaceutical Review

FEBRUARY 23, 2023

Two newer simplified treatment options are at least as effective as standard of care in achieving viral suppression, according to results from a world-first international study into second-line human immunodeficiency virus (HIV) therapy. D2EFT enrolled 831 patients from 14 countries. Patients were randomised to one of the three arms.

97

97

Outsourcing Pharma

MAY 17, 2022

The agency has removed the hold placed on the pharmaceutical companyâs IND for injectable lenacapavir, which is intended for HIV treatment and prevention.

FDA 52

FDA 52

Fierce Healthcare

DECEMBER 6, 2023

Jefferson Health has announced the launch of a recent program focused on primary care for Philadelphia’s aging LGBTQ+ community. | Pride at the Jefferson Center for Healthy Aging is said to be the first of its kind, combining clinical care and research efforts to create a primary care clinic for LGBTQ+ older adults.

74

74

Pharmacy Times

NOVEMBER 2, 2023

Paul Rainville, PharmD, CSP, AAHIVP, a clinical pharmacist and subject matter expert with Shields Health Solutions, discussed the current state of HIV in the United States

65

65

Pharmacy Times

NOVEMBER 20, 2023

In the second part of his interview with Pharmacy Times, PharmD, CSP, AAHIVP, a clinical pharmacist and subject matter expert with Shields Health Solutions, discussed pharmacists’ role in HIV education and management.

65

65

STAT

SEPTEMBER 13, 2023

In the clinic where I work, I met a patient the other day whom I might not have 20 years ago. He told me that during an emergency medical procedure, in a rural village where he was doing fieldwork, he contracted HIV. He was from Uganda. Recently, he had moved to my small university town a few hours outside of Toronto.

135

135

Pharmaceutical Technology

AUGUST 23, 2022

Gilead Sciences has obtained the European Commission (EC) marketing authorisation for Sunlenca (lenacapavir) injection and tablets to treat human immunodeficiency virus (HIV) infection. A long-acting HIV capsid inhibitor, lenacapavir has a multi-stage mechanism of action. A decision on the approval is anticipated by 27 December.

FDA 119

FDA 119

STAT

JUNE 5, 2023

Similar to earlier contraceptive mandate cases, Braidwood involves plaintiff-employers who object to paying for health insurance that includes coverage of disease screenings and PrEP for HIV on moral grounds. Their legal claims challenge the U.S. The decision was stayed by the 5th Circuit on May 15 pending its decision on appeal.

Insurance 96

Insurance 96

European Pharmaceutical Review

NOVEMBER 17, 2022

An innovative ingestible sensor technology tested in an interventional clinical trial provided HIV patients with real-time antiretroviral dosage data , enabling them to better control their infection. The study is one of earliest that uses an FDA-approved ingestible sensor system for ARV therapy in HIV-infected adults.

Dosage 93

Dosage FDA 93

Pharmacy Times

SEPTEMBER 13, 2023

Telemedicine approaches for HIV can help reduce stigma that is often a challenge in face-to-face clinical settings and eliminate common logistical barriers, such as transportation.

65

65

European Pharmaceutical Review

NOVEMBER 30, 2022

The European Commission (EC) has granted the first paediatric marketing authorisation for Gilead’s new low-dose tablet Biktarvy ® (bictegravir 30mg/emtricitabine 120mg/tenofovir alafenamide 15mg) in the European Union (EU) to treat human immunodeficiency virus (HIV). A milestone in the journey to overcoming HIV.

Adverse Reactions 91

Adverse Reactions Labelling Dosage 91

The Guardian - Pharmaceutical Industry

SEPTEMBER 28, 2023

GSK-controlled company works on developing patient-administered treatment by end of the decade One of the world’s largest commercial developers of HIV drugs is working on a treatment that can be injected by patients at home every two to three months by the end of the decade, saving them frequent visits to the clinic.

69

69

European Pharmaceutical Review

DECEMBER 23, 2022

The US Food and Drug Administration (FDA) has approved Gilead’s Sunlenca (lenacapavir), a capsid inhibitor for adults living with human immunodeficiency virus type 1 (HIV-1), who cannot be successfully treated with other available treatments. After 52 weeks, 83 percent of participants continued to have HIV RNA suppression.

FDA 88

FDA Adverse Reactions Labelling 88

Pharmacy Times

SEPTEMBER 20, 2022

Revised program will analyze the once-daily oral combination of doravirine 100 mg and a lower dose of islatravir in adults with HIV-1 infection.

65

65

Pharmacy Times

JULY 10, 2023

Despite an increase in HIV and poorer clinical outcomes among migrant populations, the uptake of PrEP among these individuals has been understudied.

65

65

European Pharmaceutical Review

AUGUST 25, 2022

The European Commission (EC) has granted marketing authorisation to a new, twice yearly treatment option for people whose HIV no longer effectively responds to their current therapy. Lenacapavir provides an innovative long-acting HIV therapy option with the potential to transform the clinical landscape.”.

Hospitals 84

Hospitals 84

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117

Vaccines Immunization 117

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. The product will be given to HIV patients whose previous HBV vaccination failed to prevent against the virus.

Vaccines 81

Vaccines Immunization FDA 81

European Pharmaceutical Review

MAY 16, 2023

1 Since the first therapy using stem cells was developed in 1957, only few stem cell-based therapies have entered the clinic 1 as advanced therapy medicinal products (ATMPs). in a 2023 paper published in the Journal of Clinical Microbiology. To facilitate this, regulation of cell therapies has transformed at pace in recent decades.

Hospitals 91

Hospitals 91

Pharmaceutical Technology

FEBRUARY 19, 2024

S-365598 is under clinical development by ViiV Healthcare and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS).

40

40

Pharmafile

MARCH 13, 2023

Gilead Sciences, a research-based biopharmaceutical company, has won again in the lawsuit levelled against clinics, prescribers, medical labs and pharmacies in relation to fraudulent claims for HIV medications. read more

52

52

Pharmacy Times

OCTOBER 10, 2022

Clinical studies have shown similar efficacy between emtricitabine and tenofovir alafenamide (Descovy) and emtricitabine and tenofovir disoproxil fumarate (Truvada) for individuals at risk for HIV infection.

65

65

Pharmacy Times

OCTOBER 28, 2022

New clinical outcomes from BICSTaR study indicate sustained impact of the therapy for individuals with HIV.

73

73

Pharmaceutical Technology

DECEMBER 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Sunlenca (lenacapavir) plus other antiretroviral(s) (ARV) to treat human immunodeficiency virus type 1 (HIV-1) infection. A long-acting HIV capsid inhibitor, Sunlenca is intended for dosing twice a year.

FDA 59

FDA 59

STAT

DECEMBER 20, 2022

Beginning in 2018 and through 2021, CytoDyn and its former CEO Nadir Pourhassan told investors repeatedly that a clinical trial had successfully demonstrated the effectiveness of an experimental treatment for HIV, and that a completed marketing application had been submitted to the U.S. Food and Drug Administration.

97

97

Outsourcing Pharma

SEPTEMBER 1, 2021

Johnson & Johnson has announced results from the primary analysis of its Imbokodo Phase 2b HIV vaccine clinical trial, with data showing the investigational HIV vaccine candidate did not provide sufficient protection against HIV infection.

Vaccines 64

Vaccines 64

pharmaphorum

DECEMBER 2, 2022

New research from ViiV Healthcare has revealed a widespread gap in public knowledge and understanding of HIV worldwide, with three-quarters of people reporting that there are still negative perceptions of people living with HIV. Person-first language must be the absolute norm to help challenge HIV-related stigma and discrimination.

52

52